M David ADAMS

Rhumatologue

RPPS 10001241495

📊 Reconnaissance scientifique : 114/100📝 963 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 19/05/2026

Le Dr David ADAMS est un rhumatologue avec une production scientifique importante, comme en témoignent son h-index élevé et son grand nombre de publications. Ses recherches portent principalement sur la génomique et la génétique, notamment dans le contexte du cancer. Ses travaux couvrent également des aspects épidémiologiques et des études de cas dans des populations variées.

Expertises présumées

Génétique du cancer
Épidémiologie génétique
Pédiatrie rhumatologique
Fatigue et santé mentale
Recherche en génomique
Études de cas en vraie vie (RWE)
Méthodes de diagnostic génétique

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

114

114 articles ont été cités au moins 114fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Influenza-Associated Acute Necrotizing Encephalopathy in US Children

JAMA · 2025

📚 13 citations🎯 RCR 5.64🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

ImportanceAcute necrotizing encephalopathy (ANE) is a rare, but severe, neurologic condition for which epidemiologic and management data remain limited. During the 2024-2025 US influenza season, clinicians at large pediatric centers anecdotally reported an increased number of children with influenza-associated ANE, prompting this national investigation.ObjectiveTo understand the clinical presentation, interventions, and outcomes among US children diagnosed with influenza-associated ANE.Design, Setting, and ParticipantsThis study was a multicenter case series of children diagnosed with ANE with longitudinal follow-up. A call for cases was issued via academic societies, public health agencies, and by directly contacting pediatric specialists at 76 US academic centers, requesting cases between October 1, 2023, and May 30, 2025. Inclusion criteria required acute encephalopathy with radiologic evidence of acute thalamic injury and laboratory confirmation of influenza infection in individuals aged 21 years or younger.ExposureInfluenza-associated ANE.Main Outcomes and MeasuresPresenting symptoms, vaccination history, laboratory and genetic findings, interventions, and clinical outcomes, including modified Rankin Scale score (0: no symptoms; 1-2: mild disability; 3-5: moderate to severe disability; 6: death), length of stay, and functional outcomes.ResultsOf 58 submitted cases, 41 cases (23 females; median age, 5 years [IQR, 2-8]) from 23 US hospitals met inclusion criteria. Thirty-one cases (76%) had no significant medical history; 5 (12%) were medically complex. Clinical presentation included fever in 38 patients (93%), encephalopathy in 41 (100%), and seizures in 28 (68%). Thirty-nine patients (95%) had influenza A (14 with A/H1pdm/2009, 7 with A/H3N2, and 18 with no subtype) and 2 had influenza B. Laboratory deviations included elevated liver enzymes (78%), thrombocytopenia (63%), and elevated cerebrospinal fluid protein (63%). Among 32 patients (78%) with genetic testing, 15 (47%) had genetic risk alleles potentially related to risk of ANE including 11 (34%) with RANBP2 variants. Among 38 patients with available vaccination history, only 6 (16%) had received age-appropriate seasonal influenza vaccination. Most patients received multiple immunomodulatory treatments, including methylprednisolone (95%), intravenous immunoglobulin (66%), tocilizumab (51%), plasmapheresis (32%), anakinra (5%), and intrathecal methylprednisolone (5%). Median intensive care unit and hospital lengths of stay were 11 days (IQR, 4-19) and 22 days (IQR, 7-36), respectively. Eleven patients (27%) died a median of 3 days (IQR, 2-4) from symptom onset, primarily from cerebral herniation (91%). Among the 27 survivors with 90-day follow-up, 63% had at least moderate disability (modified Rankin Scale score ≥3).Conclusions and RelevanceIn this case series of children with influenza-associated ANE from the 2 most recent influenza seasons in the US, the condition was associated with high morbidity and mortality in this cohort of predominantly young and previously healthy children. The findings emphasize the need for prevention, early recognition, intensive treatment, and standardized management protocols.

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

The New England journal of medicine · 2025

📚 10 citations🎯 RCR 3.66🩺 Clinique

Synthetic lethality in cancer drug discovery: challenges and opportunities

Nature reviews. Drug discovery · 2026

📚 7 citations🎯 RCR 7.00

Cookies & analyse de trafic

M David ADAMS

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Articles de presse (4)

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal32

Génétique7

Épidémiologie & registres3

Revue générale3

Pédiatrie2

Santé mentale / fatigue2

Vraie vie / RWE2

Case report / série1

IA en rhumatologie1

Pharmacovigilance1

Revue / méta-analyse1

Datasets & protocoles partagés

Partager cette fiche